Clinical studies of IG-001 performed in the United States and other countries such as Korea and Russia, have demonstrated similar clinical activity as albumin-bound paclitaxel (Abraxane??) in patients with metastatic breast cancer, non-small cell lung cancer, advanced pancreatic cancer and ovarian cancer.